Bullock_2002_Br.J.Psychiatry_180_135

Reference

Title : New drugs for Alzheimer's disease and other dementias - Bullock_2002_Br.J.Psychiatry_180_135
Author(s) : Bullock R
Ref : British Journal of Psychiatry , 180 :135 , 2002
Abstract :

BACKGROUND Alzheimer's disease management involves symptomatic drug treatments passed by the National Institute for Clinical Excellence. Disease modification is now the goal. AIMS: To review current and developmental drugs for Alzheimer's disease, their usage, and the clinical context of known facts and proposed specific models. METHOD: A brief evidence-based review was made, using literature where available, or evidence from consensus groups where it was absent. RESULTS: There is good evidence to support the use of cholinesterase inhibitors, and perhaps vitamin E. Oestrogen and anti-inflammatory agents show possibility, but there is not enough evidence to support routine use.
CONCLUSIONS: Symptomatic treatments exist for Alzheimer's disease. Observational studies and increasing knowledge of brain biology are leading towards further treatment options. Old age psychiatrists have valuable treatments they now have to learn to use.

PubMedSearch : Bullock_2002_Br.J.Psychiatry_180_135
PubMedID: 11823323

Related information

Citations formats

Bullock R (2002)
New drugs for Alzheimer's disease and other dementias
British Journal of Psychiatry 180 :135

Bullock R (2002)
British Journal of Psychiatry 180 :135